



[Go to Product page](#)

Datasheet for ABIN1027695
anti-CD79b antibody (FITC)

3 Images

6 Publications

Overview

Quantity:	100 tests
Target:	CD79b (CD79B)
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This CD79b antibody is conjugated to FITC
Application:	Flow Cytometry (FACS)

Product Details

Immunogen:	Fraction of Ig-associated molecules isolated from Ramos B cells
Clone:	CB3-1
Isotype:	IgG1 kappa
Specificity:	The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex.
Cross-Reactivity (Details):	Human
Purification:	Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Target Details

Target:	CD79b (CD79B)
---------	---------------

Target Details

Alternative Name:	CD79b (CD79B Products)
Background:	CD79b molecule,CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.,BCR beta, Ig-beta, B29, IGB
Gene ID:	974
UniProt:	P40259
Pathways:	BCR Signaling

Application Details

Application Notes:	Flow cytometry: The reagent is designed for analysis of human blood cells using 4 µL reagent / 100 µL of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Comment:	The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
Restrictions:	For Research Use only

Handling

Reconstitution:	No reconstitution is necessary.
Buffer:	Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice:	Do not freeze.

Handling

Avoid prolonged exposure to light.


Storage: 4 °C

Storage Comment: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Publications

- Product cited in:
- Dornan, Bennett, Chen, Dennis, Eaton, Elkins, French, Go, Jack, Junutula, Koeppen, Lau, McBride, Rawstron, Shi, Yu, Yu, Yue, Zheng, Ebens, Polson: "Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma." in: **Blood**, Vol. 114, Issue 13, pp. 2721-9, (2009) ([PubMed](#)).
- Zheng, Fuji, Elkins, Yu, Fuh, Chuh, Tan, Hongo, Raab, Kozak, Williams, McDorman, Eaton, Ebens, Polson: "In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates." in: **Molecular cancer therapeutics**, Vol. 8, Issue 10, pp. 2937-46, (2009) ([PubMed](#)).
- Matutes: "New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders." in: **Journal of clinical pathology**, Vol. 55, Issue 3, pp. 180-3, (2002) ([PubMed](#)).
- DArena, Cascavilla, Musto, Colella Bisogno, Pistolese, Carotenuto: "CD79b expression in B-cell chronic lymphocytic leukemia." in: **Haematologica**, Vol. 85, Issue 5, pp. 556-7, (2000) ([PubMed](#)).
- Rassenti, Kipps: "Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion." in: **Blood**, Vol. 95, Issue 8, pp. 2725-7, (2000) ([PubMed](#)).

There are more publications referencing this product on: [Product page](#)



Flow Cytometry

Image 1. Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD79b (CB3-1) FITC antibody (4 μ L reagent / 100 μ L of peripheral whole blood).

Flow Cytometry

Image 2. Flow cytometry multicolor surface staining pattern of human lymphocytes using anti-human CD19 (LT19) APC antibody (10 μ L reagent / 100 μ L of peripheral whole blood) and anti-human CD79b (CB3-1) FITC antibody (4 μ L reagent / 100 μ L of peripheral whole blood).

Flow Cytometry

Image 3. Separation of human CD79b positive B cells (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD79b (CB3-1) FITC antibody (4 μ L reagent / 100 μ L of peripheral whole blood).